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Abstract
Inhibin B has been identified as a potential marker of Sertoli cell function in males. The aim
of this study is to produce a normative model of serum inhibin B in males from birth to seven-
teen years. We used a well-defined search strategy to identify studies containing data that
can contribute to a larger approximation of the healthy population. We combined data from
four published studies (n = 709) and derived an internally validated model with high good-
ness-of-fit and normally distributed residuals. Our results show that inhibin B increases fol-
lowing birth to a post-natal peak of 270 pg/mL (IQR 210–335 pg/mL) and then decreases
during childhood followed by a rise at around 8 years, peaking at a mean 305 pg/mL (IQR
240–445 pg/mL) at around age 17. Following this peak there is a slow decline to the stan-
dard mature adult normal range of 170 pg/mL (IQR 125–215 pg/mL). This normative model
suggests that 35% of the variation in Inhibin B levels in young males is due to age alone,
provides an age-specific reference range for inhibin B in the young healthy male population,
and will be a powerful tool in evaluating the potential of inhibin B as a marker of Sertoli cell
function in pre-pubertal boys.
Introduction
Inhibin B is a member of the transforming growth factor beta family of growth factors, and in
males is secreted by the Sertoli cells of the testis that are located on the basement membrane of
the seminiferous tubules, and nurture and support spermatogenesis. There is a well described
negative feedback relationship, which becomes established around puberty [1, 2], with Follicle
Stimulating Hormone (FSH) released from the anterior pituitary [3] under the control of
gonadotrophin releasing hormone from the hypothalamus. Serum levels of inhibin B in adults
have been shown to correlate positively with spermatogenesis [4–6]. Little is known about the
significance of inhibin B levels in children [4, 7–10].
In a retrospective longitudinal study we have previously shown a potential role for inhibin B
to predict fertility outcome in young males [11]. In adults the first study to report serum
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inhibin B as a marker of Sertoli cell function after chemotherapy was Wallace EM et al. (1997)
[12], and a study by van Beek et al (2007) reported inhibin B as a marker of Sertoli cell damage
in children treated for Hodgkin lymphoma [13]. However the interpretation of a marker of Ser-
toli cell function in young males requires an age-related normative model that quantifies the
qualitative assessments of high neonatal inhibin B [14] followed by lower levels during child-
hood (although higher than that of females) [2, 15, 16]. Therefore the aim of this study was to
identify and corroborate all studies containing data on the level of inhibin B and produce, and
derive a normative model of inhibin B from birth to the age of seventeen years.
Methods
We searched two databases, Pubmed and Medline, for the search term inhibin B. The last
search was performed in August 2015. Abstracts were studied, duplicates removed, and initial
exclusion criteria applied. The exclusion criteria included, papers that were not written in
English, those not containing humans and those not containing serum inhibin B levels. Full-
text papers were then studied and further exclusion criteria applied to rule out studies not
involving healthy male subjects, containing data that was not in an extractable form, not con-
taining the correct age range, and using pubertal (i.e. Tanner) stage rather than age. The refer-
ence lists of selected studies were checked to identify further relevant studies. Data was mined
from charts in the 4 identified studies (Table 1) using Web Plot Digitizer v3.9 [17] to convert
datapoints into paired numerical values signifying age and inhibin B level (S1 Dataset). Each of
the included studies used the same two-site ELISA assays with antibodies for Inhibin alpha and
beta subunits developed by Groome et al [18]. The longitudinal data in each were treated as
cross-sectional for model derivation. The resulting combined dataset (n = 709, median age 4.9
years, range 0–17 years) provides a sample that approximates the distribution of inhibin B lev-
els in healthy human males for these ages (Fig 1).
Approval was not required from an ethics committee or institutional review board since our
research was limited to use of previously collected, non-identifiable data that has been pub-
lished in peer reviewed journals which is specifically excluded from Research Ethics Committee
review by the National Research Ethics Service guidelines of the UK Health Research Agency
[19]. Patient data were anonymized and de-identified by the researchers involved in the pub-
lished studies, prior to our analysis. Written informed consent was obtained from participants
(or next of kin/caregiver in the case of children) for their clinical data to be published in the
studies that provided the data that we extracted to derive our normative model. No patient
identifiable information was available to us at any stage of our investigation.
We used an established methodology [20–23] to construct a normative model for Inhibin B.
Inhibin B level at conception is known to be zero, so datapoints were added that forced models
to go through this point (these additions were later deleted when assessing models by coeffi-
cient of determination and residual normality). Reference values for adults [24] were added to
Table 1. Summary of Inhibin B data. Year of publication first author and Pubmed ID for the papers used for data extraction, together with individual and
combined study sizes and age statistics.
Year 1st Author PMID n Median age Age range
1998 Andersson 9467591 133 1 year 0–2 years
2005 Radicioni 15757857 96 10.5 years 1.5–16.9 years
2002 Crofton 11874413 366 8.6 years 0–17 years
2006 Bergada 16849404 114 2.5 days 1–36 days
Total 709 4.9 years 0–17 years
doi:10.1371/journal.pone.0153843.t001
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ensure correctness at ages above 17 years. To guard against sensitivity of the model at younger
ages to the values imputed, model fitting following the random generation of adult values was
repeated a total of ten times, with the imputed values included when assessing coefficient of
determination and residual normality. Most studies of inhibin B report square-root adjusted
values as levels are skew-normally distributed at given ages. Box-Cox analysis of our combined
data showed an expected level of skewness that can be resolved by square-root adjustment—
optimal lambda = 0.58 (95% CI 0.54–0.60)—which was performed before the model evaluation
stage. TableCurve-2D (Systat Software Inc., San Jose, California, USA) was used to generate
255 mathematical models, which demonstrated predicted inhibin B level, 95% confidence lim-
its for the model, and 95% prediction limits. The models were then evaluated for goodness of
fit (using the r2 coefficient of determination) and normality of residuals (by comparing residual
histograms to an idealised Gaussian distribution). The Akaike information criterion (the other
common measure of goodness of fit for predictive models) was not calculated, since is equiva-
lent to the r2 coefficient of determination for the linear least square regression models under
consideration, with both measures being directly related to the residual sum of squares for a
candidate model. We assessed candidate models for underfit (i.e low r2 due to insufficient
Fig 1. Root transformed Inhibin B levels. The red line is the model that best fits the 709 data points, which are indicated by blue squares. The model has r2
= 0.35, indicating that 35% of the variation in inhibin B levels in young males is due to age alone. The green lines represent the upper and lower 95%
confidence limits for the predicted mean and the orange lines the upper and lower 95% prediction limits.
doi:10.1371/journal.pone.0153843.g001
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complexity of the model in terms of number of model parameters) and overfit (i.e. models that
are complex enough to obtain high r2 for the supplied data but which are also likely to have
high error when generalised new data). To guard against models being selected by chance con-
figuration of the data two forms of internal validation were implemented. 5-fold cross-valida-
tion was performed with residual mean training error for five randomly-chosen 80% subsets of
the data compared to residual mean test error for the 20% subsets not used to fit the model.
Bootstrap validation was performed on each candidate model by 2000 iterations of selecting
with replacement ages and root-transformed pairs at random from the data, calculating the
mean square error for each sample, and estimating the extra-sample prediction error by the
mean of the bootstrap mean square errors.
Results
The search for the term Inhibin B in Pubmed and Medline generated 1568 results, yielding 871
unique sources after removal of duplicates. The initial exclusion criteria were applied to the
abstracts, resulting in 51 full-text studies being analysed and further exclusion criteria applied.
Four papers were selected for quantitative synthesis in this study (Table 1).
The best performing class of models in terms of r2 and residual normality were rational
polynomials. Models having fewer than 8 parameters displayed considerable underfit to the
data, with r2 values over 10% lower than for the 8-parameter model. An 11-parameter model
had higher r2 and lower residual mean error than the 8-parameter model, but this increase in
model performance involved negative inhibin B values between conception and birth (which
are impossible in reality) and less normally-distributed residuals (94% agreement with a perfect
Gaussian distribution as against 97%). Estimates of generalisation error obtained from 5-fold
cross validation and 2000 bootstrap samples were within 1% of each other for all models. We




¼ aþ cx þ ex
2 þ gx3
1þ bx þ dx2 þ fx3 þ hx4
where IB denotes inhibin B in pg/mL and x denotes age in years (Fig 1). The parameter values
for a, b, . . ., h are given in Table 2, along with 95% conﬁdence intervals, standard errors and T-
values. The residuals for this model are shown in Fig 2; these have 97% agreement with a per-
fect normal distribution. The coefﬁcient of determination r2 = 0.35, indicating that 35% of the
variation in inhibin B levels for these ages is due to age alone, with the remaining 65% due to
other factors such as genetics, lifestyle and Tanner stage. The repeated imputation of adult
inhibin B values had no appreciable effect on the derivation of the model for ages 0–17 years,
Table 2. Parameter values for the normative model. The 8 parameter values for the model shown in Fig 2, together with their standard error, T statistics
and 95% confidence limits.
Parameter Value Std Error T Value 95% CL 95% CL
a 15.4403 0.2607 59.2154 14.9287 15.9520
b 0.8408 0.1133 7.4214 0.6185 1.0631
c 19.6695 0.9737 20.2015 17.7590 21.5800
d 0.4985 0.1998 2.4954 0.1065 0.8904
e -1.0425 1.2055 -0.8648 -3.4081 1.3230
f -0.0402 0.0140 -2.8705 -0.0677 -0.0127
g 0.2895 0.0682 4.2462 0.1557 0.4233
h 0.0015 0.0003 4.9879 0.0009 0.0020
doi:10.1371/journal.pone.0153843.t002
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since the model parameters obtained for each instance were similar (Table 3), being in each
case within the 95% conﬁdence intervals for the reported model. The model has a residual
mean error of 8.1 pg/ML (square-root adjusted) for the entire dataset. The residual mean train-
ing error after 5-fold validation is also 8.1 pg/ML (square-root adjusted), with residual mean
test error of 8.3 pg/ML (square-root adjusted).
Fig 2. Model residuals. The residuals are the variations in root-adjusted observed values from the root-adjusted age-related mean value predicted by the
model. The residuals have 97% goodness of fit to an ideal Gaussian curve.
doi:10.1371/journal.pone.0153843.g002
Table 3. Imputed data analysis. 300 randomly imputed adult data points were added to our combined data before fitting and comparing normative models.
This was repeated for a total of 10 imputations, with model parameters collected for comparison and shown in the numbered columns. For any choice of
instance, the parameters are within the 95% confidence intervals for each of the remaining instances.
Parameter 1 2 3 4 5 6 7 8 9 10
a 15.4403 15.4407 15.4392 15.4258 15.4392 15.4388 15.4413 15.4365 15.4384 15.4392
b 0.8408 0.8412 0.8395 0.8235 0.8394 0.8389 0.8418 0.8362 0.8385 0.8394
c 19.6695 19.6666 19.6810 19.8309 19.6817 19.6856 19.6624 19.7099 19.6898 19.6816
d 0.4985 0.4976 0.5017 0.5422 0.5018 0.5029 0.4963 0.5096 0.5041 0.5018
e -1.0425 -1.0482 -1.0249 -0.8061 -1.0241 -1.0179 -1.0569 -0.9816 -1.0115 -1.0240
f -0.0402 -0.0404 -0.0403 -0.0426 -0.0403 -0.0403 -0.0407 -0.0406 -0.0403 -0.0403
g 0.2895 0.2880 0.2903 0.2906 0.2900 0.2907 0.2853 0.2915 0.2910 0.2903
h 0.0015 0.0015 0.0015 0.0015 0.0015 0.0015 0.0015 0.0015 0.0015 0.0015
doi:10.1371/journal.pone.0153843.t003
A Normative Model of Inhibin B
PLOSONE | DOI:10.1371/journal.pone.0153843 April 14, 2016 5 / 10
Our model shows that inhibin B rises from a mean level of 240 pg/mL (IQR 185–300 pg/
mL) at birth in males and reaches a post-natal peak of 270 pg/mL (IQR 210–335 pg/mL) at
around 3 months old (Fig 3; Table 4). The level then decreases and remains between 80 and 90
pg/mL (IQR 50–130 pg/mL) for ages 4 to 7 years. Inhibin B begins to rise at around 8 years,
peaking at 305 pg/mL (IQR 240–445 pg/mL) at around age 17. Following this peak there is a
slow decline to the standard mature adult reference level of 170 pg/mL (IQR 125–215 pg/mL).
Discussion
We have derived a normative model of inhibin B for a healthy human population of males
from birth to the age of seventeen. We have shown that, in males, levels of inhibin B rise from
birth to a post-natal peak, only to decrease to low, but still measurable, levels during childhood,
and increase again from approximately 8 years of age to reach a peak around 17 years old. Our
internal validation results suggest that (a) the optimal model is not obtained by a chance selec-
tion of suitable data, (b) the reported model is neither over- nor underfitting the data, and (c)
the generalisation error when using the model to predict new values is likely to be low.
The finding of a post-natal peak is in keeping with a number of studies. Chada et al, (2003)
reported that inhibin B showed a significant increase to a peak at 3–4 months of age and a
decrease at 5–11 months [25]. This trend was also a finding by Byrd et al (1998), who showed
that males between 13 weeks and 1 year had higher inhibin B levels than post-pubertal males
[26]. Our study confirms the finding by Andersson et al (1998) that the post-natal peak exceeds
Fig 3. The Normative Model. Inhibin B levels in humanmales from birth to age 17 years expressed as standard centiles.
doi:10.1371/journal.pone.0153843.g003
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the level of inhibin B found in adult men [7]. The post-natal peak most likely reflects the activa-
tion of the hypothalamic pituitary gonadal axis, as the number of Sertoli cells in males during
the first year of life can increase fivefold [27]. This is comparable to the increase in AMH that
is seen in females during this post-natal period [22]. This postnatal rise may therefore predict
later testicular function, in particular spermatogenesis, but longitudinal studies are required to
assess that possibility.
These data also show that there is a rise in inhibin B from age 8. Although this analysis does
not include pubertal staging, this rise in inhibin B would seem to be earlier than the clinical
onset of puberty, likely reflecting prepubertal proliferation of Sertoli cells [28, 29]. The onset of
puberty is classically defined by an increase in testicular volume with rising testosterone levels,
with mean age of onset at 11.5 years in males [30]: thus the present analysis indicates that there
are significant maturational events occurring in the testis before the clinical onset of puberty.
The production of significant levels of inhibin B in pre-pubertal males demonstrates that basal
inhibin B secretion takes place in the prepubertal testis, despite the very low levels of both
gonadotrophins and testosterone [4]. Therefore, one clinical implication of our normative
model is its potential use as a reference for a healthy population in assessing the role of inhibin
B as a pre-pubertal marker of Sertoli cell function. This has a number of potential clinical
implications, including the assessment of functioning testicular tissue in hypogonadotrophic
hypogonadism, anorchia and disorders of sexual development [2, 31]. We have reported our
experience in assessing inhibin B as a marker of gonadotoxicity in young males treated for
malignancy in childhood [11], but the interpretation was limited by the absence of a normative
model for inhibin B in childhood.
We have also shown that there is a pubertal peak, as the level at about 17 years old exceeds
that of the adult [24]. This is in keeping with a study by Andersson et al (1997), whose results
suggest a slight decrease in the level of inhibin B post-pubertally [4]. A study to assess serum
inhibin B levels in normal men showed an age-related decline of median inhibin B levels
Table 4. Normative Inhibin B levels in pg/mL. The centiles shown in Fig 3 are here given in tabular form for each year from birth to 17 years.
Age 2.5th centile 10th centile 25th centile 50th centile 75th centile 90th centile 97.5th centile
0 99 140 183 238 301 362 439
1 89 129 170 223 283 343 418
2 43 72 104 146 196 246 310
3 23 46 71 107 150 195 251
4 16 34 57 90 129 171 224
5 13 31 52 84 122 162 214
6 14 31 53 85 123 164 216
7 17 36 59 92 131 173 227
8 22 43 68 103 145 189 245
9 29 53 81 119 164 210 269
10 40 67 98 139 187 236 299
11 53 84 118 162 214 267 333
12 68 103 140 188 244 300 370
13 85 123 164 216 275 335 408
14 102 144 188 243 306 368 444
15 118 163 209 268 333 398 478
16 132 179 228 289 357 424 506
17 141 191 241 304 374 444 528
doi:10.1371/journal.pone.0153843.t004
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limited to the younger age groups, with stable levels between age 35 and 79 years, and only a
modest further decrease thereafter [32].
It is interesting that, in males, inhibin B peaks at a younger age (17 years in our model) than
testosterone, which peaks at 19 years [21]. We know from longitudinal studies that spermarche
occurs at a median age of 13.4 years (IQR 11.7–15.3 years), with spermatozoa being found in
the urine of boys in early puberty [33]. It appears likely that maturation of Sertoli cells to sup-
port spermatogenesis can occur in the presence of sub maximal levels of testosterone.
This study has a number of limitations, including its relative small size and different storage
procedures for the samples. Crofton et al (2002) reported storing samples for up to eight years
at -80°C before analysis [8], but the length of storage is not stated in the other papers. Timing
of sample collection varies between studies, however the diurnal variation in serum inhibin B is
on average only 3% with higher levels in the morning [34]. This variation is within the limits of
the assay accuracy and is therefore unlikely to introduce significant bias. Our treatment of lon-
gitudinal data as cross-sectional may have reduced the variability in Inhibin B in our reported
model. However, correct variability was enforced for younger ages (i.e. zero Inhibin B at con-
ception) and ages above 17 years (using data imputed from adult reference ranges derived
from cross-sectional data), and the use of these values guards against a significant underesti-
mate of the true variability in Inhibin B levels for ages 0–17 years.
In summary we have described a normative model of inhibin B for young males from birth
to aged 17 years. We believe this will be an invaluable tool as a reference model for evaluating
the role of inhibin B as a marker of Sertoli cell function in the younger male.
Supporting Information
S1 Dataset. Combined Inhibin B data and validation subsets. The combined worksheet has
the 709 extracted age-inhibin B pairs, together with imputed values at age 30 and fixed zero val-
ues at conception. Raw values in pm/mL are square root adjusted. The Xi columns are the
10-fold imputation variants. The Kj worksheets contain the 80% of the data used for training at
each validation fold, together with the 20% remainder used as test data.
(XLS)
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